SMi's 9th Annual Conference: Biobanking 2019

SMi Group25 - 26 September 2019, London, UK.
With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020, backed by an explosive CAGR of 9.5% between now and 2026. This market growth is fuelled by the increasing drive towards precision and personalised medicine and thus, quality biosamples are now in soaring demand.

Come join Biobanking 2019 in September 2019 and; thoroughly understand the latest developments in the biobanking industry; network with the industry experts and key opinion leaders; gain insight into how the biobanking industry at the forefront at driving precision medicine and enhancing research and discover 'Drone4Care', how drone delivery of biosamples can be a reality.

The event will bring together internationally recognised biorepositories, scientific pioneers from pharmaceutical companies, and academics to strengthen current knowledge in biosample management and their research applications. We will cover the most relevant hot topics including: the latest biorepository technological breakthroughs, the best practices in biobanking, shifts in the biosample regulation landscape, the international biobank societies with ESBB and ISBER, along with a whole host of successful biobanking business model structures to help reinvigorate your biobank.

Benefits of attending

  • Discover 'Drone4care' from Laurent Dollé, the innovative and daring plan to use drones for the delivery of biomaterial. Additionally, he will be detailing the new promising technology of Tissue Microarray, a bioprocessing technology that can reduced the number of needed biosamples for research from 200 down to 1
  • Hear from UK Biobank on the continual impact of GDPR on the biobanking landscape
  • Learn about a diverse range of the most successful biobanking business models from real case studies
  • Gain insight from the global biobank collaboration societies of ESBB and ISBER, see how you can place your biobank on the international stage

For further information and to register, please visit:
http://www.biobanking-event.com/wpnwl

Early bird rates

  • Book by 30th April and save £400
  • Book by 31st May and save £300
  • Book by the 28th June and save £200

Plus, two interactive half day pre-conference workshops:

Workshop A: Reinvigorate your through data quality enhancement and Financial and Economic tools
Workshop Leader:Laurent Dollé, Managing Director, BWB (BiothèqueWallonieBruxelles)
8:30 - 12:30

Workshop B: The Organic Development of a Sustainable Academic Biobank
Workshop Leader:Mary-Beth Joshi, Director, Biobank & translational Research Core, Duke University Medical Centre
1:30 - 5:30

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Novartis signs initial agreement to reserve capaci…

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (...

Pfizer acquires Amplyx Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilita...

Moderna announces additional investments to increa…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is making new funding commitments to i...

Moderna announces emergency use listing granted by…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has is...

Sanofi to help manufacture Moderna COVID-19 vaccin…

Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine suppl...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Speeding new treatments

A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-Co...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Brazilian coronavirus variant likely to be more tr…

Even though more and more vaccines against the coronavirus are being administered all over the world, many countries are still battling with outbreaks and face difficulti...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Updated results on coronavirus vaccination effecti…

Several weeks following the publication of the large real-world COVID-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard Univer...

Our immune systems blanket the SARS-CoV-2 spike pr…

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus resp...